|
|
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32327431|t=2020. Keeping up with studies on covid-19: systematic search strategies and resources |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32202343|t=ä. Systematic review of COVID?19 in children shows milder cases and a better prognosis than adults |pdf=|usr=}}
| |
| − | {{tp|p=32196678|t=ä. Eleven faces of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32363707|t=2020. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review |pdf=|usr=}}
| |
| − | {{tp|p=32253003|t=2020. COVID-19 virus and children: What do we know?|pdf=|usr=}}
| |
| − | {{tp|p=32303495|t=2020. Clinical features of covid-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32279352|t=2020. Blood and blood product use during COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32223716|t=2020. Diagnosis and Management of COVID-19 Disease |pdf=|usr=}}
| |
| − | {{tp|p=32221973|t=2020. The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice |pdf=|usr=}}
| |
| − | {{tp|p=32189015|t=2020. "Coronavirus disease 2019" (COVID-19): update fur Anasthesisten und Intensivmediziner Marz 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32312715|t=2020. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32354810|t=2020. An alternative COVID-19 checklist |pdf=|usr=}}
| |
| − | {{tp|p=32290887|t=ä. COVID-19: What paramedics need to know!|pdf=|usr=}}
| |
| − |
| |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{ttp|p=32330073|t=2020. COVID-19 Lung Injury and High Altitude Pulmonary Edema: A False Equation with Dangerous Implications |pdf=|usr=}}
| |
| − | {{tp|p=32319081|t=2020. Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when and how?|pdf=|usr=}}
| |
| − | {{ttp|p=32358233|t=2020. Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers |pdf=|usr=}}
| |
| − | {{tp|p=32341294|t=2020. Toward Precision Delivery of Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019 Cardiorespiratory Failure |pdf=|usr=}}
| |
| − | {{tp|p=32317557|t=2020. Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32243267|t=2020. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure |pdf=|usr=}}
| |
| − | {{tp|p=32243266|t=2020. Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China |pdf=|usr=}}
| |
| − | {{tp|p=32366375|t=2020. Management of respiratory failure due to covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32229575|t=2020. Covid-19: Mercedes F1 to provide breathing aid as alternative to ventilator |pdf=|usr=}}
| |
| − | {{tp|p=32377387|t=2020. High-flow Nasal Cannula Oxygenation Revisited in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32346862|t=2020. Inhaled NO and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32102726|t=2020. Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32097201|t=2020. Non-invasive respiratory support for patients with novel coronavirus pneumonia: clinical efficacy and reduction in risk of infection transmission |pdf=|usr=}}
| |
| − | {{tp|p=32369390|t=2020. Differentiating COVID-19 Pneumonia from Acute Respiratory Distress Syndrome (ARDS) and High Altitude Pulmonary Edema (HAPE): Therapeutic Implications |pdf=|usr=}}
| |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32293905|t=2020. SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients |pdf=|usr=}}
| |
| − | {{tp|p=32338536|t=2020. A Bayesian analysis of strategies to rule out COVID19 using reverse transcriptase-polymerase chain reaction (RT-PCR) |pdf=|usr=}}
| |
| − | {{tp|p=32294808|t=2020. The Royal College of Pathologists of Australasia (RCPA) position statement on COVID-19 (serology) |pdf=|usr=}}
| |
| − | {{tp|p=32367615|t=2020. Trends and Innovations in Biosensors for COVID-19 Mass Testing |pdf=|usr=}}
| |
| − | {{ttp|p=32187837|t=2020. Supersensitive Multifluorophore RNA-FISH for Early Virus Detection and Flow-FISH by Using Click Chemistry |pdf=|usr=}}
| |
| − | {{ttp|p=32221132|t=2020. In Silico assessment of the impact of 2019 novel coronavirus (2019-nCoV) genomic variation on published real-time quantitative polymerase chain reaction detection assays |pdf=|usr=}}
| |
| − | {{tp|p=32149771|t=2020. A case of 2019 novel coronavirus infected pneumonia with twice negative 2019-nCoV nucleic acid testing within 8 days |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32275766|t=2020. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review |pdf=|usr=}}
| |
| − | {{tp|p=32298464|t=2020. Whole body point-care ultrasound for COVID-19: a multi-system approach to a multi-system disease |pdf=|usr=}}
| |
| − | {{tp|p=32357307|t=2020. Radiographic examination of the chest and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32271603|t=2020. Dynamic Chest CT Evaluation in Three Cases of 2019 Novel Coronavirus Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32282404|t=2020. Incidental CT Findings Suspicious for COVID-19?Associated Pneumonia on Nuclear Medicine Examinations: Recognition and Management Plan |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 63: |
Zeile 21: |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32348474|t=2020. Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32369402|t=2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2) |pdf=|usr=}}
| |
| − | {{tp|p=32378705|t=2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32132669|t=2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=32149770|t=2020. High-throughput sequencing for confirmation of suspected 2019-nCoV infection identified by fluorescence quantitative polymerase chain reaction |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 81: |
Zeile 33: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{ttp|p=32376393|t=ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32220633|t=2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?|pdf=|usr=}}
| |
| − | {{tp|p=32297671|t=2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32311762|t=2020. SARS-CoV-2: a new aetiology for atypical lymphocytes |pdf=|usr=}}
| |
| − | {{tp|p=32297330|t=2020. Reactive lymphocytes in patients with Covid-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32203188|t=2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
| |
| − | {{ttp|p=32203186|t=2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
| |
| − | {{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}}
| |
| − | {{tp|p=32375560|t=2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 95: |
Zeile 38: |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{ttp|p=32376400|t=ä. Cytokine storm syndrome in severe COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32376401|t=ä. Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH?|pdf=|usr=}}
| |
| − | {{tp|p=32293098|t=2020. On the Alert for Cytokine Storm: Immunopathology in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}}
| |
| − | {{tp|p=32345602|t=2020. Covid-19: concerns grow over inflammatory syndrome emerging in children |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 105: |
Zeile 43: |
| | ---- | | ---- |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32379417|t=ä. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age |pdf=|usr=}}
| |
| − | {{ttp|p=32376402|t=ä. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies |pdf=|usr=}}
| |
| − | {{ttp|p=32361194|t=ä. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons |pdf=|usr=}}
| |
| − | {{ttp|p=32323565|t=2020. Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the Observed Severity of COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32379894|t=2020. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32259373|t=2020. Cytologic and histologic samples from patients infected by the novel coronavirus 2019 SARS-CoV-2: An Italian institutional experience focusing on biosafety procedures |pdf=|usr=}}
| |
| − | {{tp|p=32346073|t=2020. COVID-19: towards understanding of pathogenesis |pdf=|usr=}}
| |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32348692|t=2020. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids |pdf=|usr=}}
| |
| − | {{tp|p=32374218|t=2020. Avian coronaviruses |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 129: |
Zeile 57: |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32173883|t=ä. COVID?19 and mycoplasma pneumoniae coinfection |pdf=|usr=}}
| |
| − | {{tp|p=32314699|t=2020. Case Report: The Importance of Novel Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32271596|t=2020. Co-infection of Coronavirus Disease 2019 and Influenza A: A Report from Iran |pdf=|usr=}}
| |
| − | {{ttp|p=32374823|t=2020. COVID-2019 associated overexpressed Prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32379863|t=ä. Metagenomic analysis reveals clinical SARS-CoV-2 infection and bacterial or viral superinfection and colonization |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 140: |
Zeile 63: |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32339221|t=2020. COVID-19 and its implications for thrombosis and anticoagulation |pdf=|usr=}}
| |
| − | {{tp|p=32374029|t=2020. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis |pdf=|usr=}}
| |
| − | {{tp|p=32369614|t=2020. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia |pdf=|usr=}}
| |
| − | {{ttp|p=32369610|t=2020. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily |pdf=|usr=}}
| |
| − | {{tp|p=32353183|t=2020. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32330308|t=2020. COVID19 coagulopathy in Caucasian patients |pdf=|usr=}}
| |
| − | {{ttp|p=32304581|t=2020. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32304577|t=2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action |pdf=|usr=}}
| |
| − | {{tp|p=32352633|t=2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients |pdf=|usr=}}
| |
| − | {{tp|p=32339025|t=2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32369626|t=2020. Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia |pdf=|usr=}}
| |
| − | {{tp|p=32374906|t=2020. Autoimmune haemolytic anaemia associated with COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32369609|t=2020. Thrombocytopenia as an initial manifestation of Covid-19; Case Series and Literature review |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32255359|t=2020. Clinical utility of cardiac troponin measurement in COVID-19 infection |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32327427|t=2020. Myositis as a manifestation of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32086236|t=2020. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear |pdf=|usr=}}
| |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32353170|t=2020. Cutaneous lesions in a patient with COVID-19: are they related?|pdf=|usr=}}
| |
| − | {{tp|p=32348545|t=2020. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32374032|t=2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors |pdf=|usr=}}
| |
| − | {{tp|p=32302212|t=2020. COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation |pdf=|usr=}}
| |
| − | {{tp|p=32339257|t=2020. Acute pancreatitis in a COVID-19 patient |pdf=|usr=}}
| |
| − | {{tp|p=32343396|t=2020. Covid-19 may present with acute abdominal pain |pdf=|usr=}}
| |
| − | {{tp|p=32371168|t=ä. The Topic of COVID-19?Related Liver Injury Needs More Rigorous Research |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32376320|t=ä. Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract |pdf=|usr=}}
| |
| − | {{tp|p=32320102|t=ä. Hydatidiform mole in the era of COVID?19 pandemic Is there an association?|pdf=|usr=}}
| |
| − | {{tp|p=32266828|t=2020. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32243894|t=2020. COVID-19 infection in cancer patients: early observations and unanswered questions |pdf=|usr=}}
| |
| − | {{tp|p=32224151|t=2020. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32241792|t=2020. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD |pdf=|usr=}}
| |
| − | {{tp|p=32354772|t=2020. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept |pdf=|usr=}}
| |
| − | {{tp|p=32332075|t=2020. Patients with lupus are not protected from COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32332072|t=2020. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine |pdf=|usr=}}
| |
| − | {{tp|p=32295789|t=2020. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327426|t=2020. SLE patients are not immune to covid-19: importance of sending the right message across |pdf=|usr=}}
| |
| − | {{tp|p=32295787|t=2020. SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment |pdf=|usr=}}
| |
| − | {{tp|p=32321720|t=2020. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) |pdf=|usr=}}
| |
| − | {{tp|p=32312768|t=2020. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32245656|t=2020. COVID-19 in patients with cardiovascular diseases |pdf=|usr=}}
| |
| − | {{tp|p=32180426|t=2020. An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32255510|t=2020. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement |pdf=|usr=}}
| |
| − | {{tp|p=32369656|t=2020. Coronavirus disease 2019 among pregnant Chinese women: case series data on the safety of vaginal birth and breastfeeding |pdf=|usr=}}
| |
| − | {{tp|p=32219995|t=2020. Safe delivery for pregnancies affected by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339382|t=2020. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis |pdf=|usr=}}
| |
| − | {{tp|p=32324956|t=2020. How should we treat pregnant women infected with SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32340018|t=2020. Coronavirus Disease 2019 in a Hemodialysis Patient |pdf=|usr=}}
| |
| − | {{tp|p=32220865|t=2020. Non-steroidal anti-inflammatory drugs and covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205306|t=2020. Covid-19: European drugs agency to review safety of ibuprofen |pdf=|usr=}}
| |
| − | {{tp|p=32184201|t=2020. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists |pdf=|usr=}}
| |
| − | {{tp|p=32253225|t=2020. Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases |pdf=|usr=}}
| |
| − | {{tp|p=32369736|t=ä. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes |pdf=|usr=}}
| |
| − | {{tp|p=32241880|t=2020. Drugs and the renin-angiotensin system in covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291262|t=2020. Covid-19: Black people and other minorities are hardest hit in US |pdf=|usr=}}
| |
| − | {{tp|p=32379903|t=2020. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32369615|t=2020. Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression |pdf=|usr=}}
| |
| − | {{tp|p=32369606|t=2020. COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience |pdf=|usr=}}
| |
| − | {{tp|p=32314798|t=2020. COVID-19 infection in patients with sickle cell disease |pdf=|usr=}}
| |
| − | {{tp|p=32333398|t=2020. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance |pdf=|usr=}}
| |
| − | {{tp|p=32312714|t=2020. COVID-19 More Frequent, Severe in Cancer Patients |pdf=|usr=}}
| |
| − | {{tp|p=32352633|t=2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients |pdf=|usr=}}
| |
| − | {{tp|p=32302248|t=2020. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − | {{tp|p=32302265|t=2020. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32339025|t=2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend |pdf=|usr=}}
| |
| − |
| |
| | *'''[[The morbid survivor]]''' | | *'''[[The morbid survivor]]''' |
| − | {{tp|p=32364491|t=ä. Are COVID-19 survivors at increased risk for suicide?|pdf=|usr=}}
| |
| − | {{tp|p=32282359|t=2020. Rehabilitation After Critical Illness in People With COVID-19 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32251003|t=2020. Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis |pdf=|usr=}}
| |
| − | {{tp|p=32251002|t=2020. Recommendations for respiratory rehabilitation in adults with COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32277694|t=2020. Case Report: Death Due to Novel Coronavirus Disease (COVID-19) in Three Brothers |pdf=|usr=}}
| |
| − | {{tp|p=32375200|t=2020. Pneumomediastinum following intubation in COVID-19 patients: a case series |pdf=|usr=}}
| |
| − | {{tp|p=32304394|t=2020. First Successful Treatment of Coronavirus Disease 2019 Induced Refractory Cardiogenic Plus Vasoplegic Shock by Combination of Percutaneous Ventricular Assist Device and Extracorporeal Membrane Oxygenation: A Case Report |pdf=|usr=}}
| |
| − | {{tp|p=32371416|t=2020. Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32255382|t=2020. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32360780|t=ä. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32298145|t=2020. Role of Data Registries in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364764|t=2020. Data quarantine in the time of the COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 255: |
Zeile 93: |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32245769|t=2020. Managing clinical trials for covid-19: the importance of ethics committees |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32329159|t=2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach |pdf=|usr=}}
| |
| − | {{tp|p=32376597|t=2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series |pdf=|usr=}}
| |
| − | {{tp|p=32345616|t=2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32304395|t=2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support |pdf=|usr=}}
| |
| − | {{ttp|p=32349115|t=ä. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380318|t=ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32380316|t=ä. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}}
| |
| − | {{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
| |
| − | {{tp|p=32376396|t=ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?|pdf=|usr=}}
| |
| − | {{tp|p=32376395|t=ä. SARS-CoV-2 infection among patients with systemic autoimmune diseases |pdf=|usr=}}
| |
| − | {{ttp|p=32376392|t=ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}}
| |
| − | {{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32376394|t=ä. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: A comprehensive review |pdf=|usr=}}
| |
| − | {{ttp|p=32376397|t=ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view |pdf=|usr=}}
| |
| − | {{tp|p=32376398|t=ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32361195|t=ä. SARS-CoV-2 infection complicated by inflammatory syndrome Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?|pdf=|usr=}}
| |
| − | {{tp|p=32304139|t=ä. Progress and Concept for COVID?19 Vaccine Development |pdf=|usr=}}
| |
| − | {{tp|p=32213152|t=2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?|pdf=|usr=}}
| |
| − | {{tp|p=32299796|t=2020. Antirheumatic agents in covid-19: is IL-6 the right target?|pdf=|usr=}}
| |
| − | {{ttp|p=32376613|t=2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |pdf=|usr=}}
| |
| − | {{tp|p=32366720|t=2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs |pdf=|usr=}}
| |
| − | {{tp|p=32312781|t=2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205349|t=2020. Updated Approaches against SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}}
| |
| − | {{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}}
| |
| − | {{tp|p=32282033|t=2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32302379|t=2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32366511|t=2020. Developing a vaccine for covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357949|t=2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers |pdf=|usr=}}
| |
| − | {{tp|p=32217607|t=2020. Covid-19: what treatments are being investigated?|pdf=|usr=}}
| |
| − | {{tp|p=32217555|t=2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients |pdf=|usr=}}
| |
| − | {{tp|p=32209549|t=2020. Covid-19: trials of four potential treatments to generate "robust data" of what works |pdf=|usr=}}
| |
| − | {{tp|p=32340998|t=2020. Covid-19: What do we know so far about a vaccine?|pdf=|usr=}}
| |
| − | {{tp|p=32321732|t=2020. Remdesivir in covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32304110|t=2020. Dosing will be a key success factor in repurposing antivirals for COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32369628|t=2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |pdf=|usr=}}
| |
| − | {{tp|p=32369612|t=2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma |pdf=|usr=}}
| |
| − | {{tp|p=32368792|t=2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{ttp|p=32358833|t=2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development IUPHAR Review 29 |pdf=|usr=}}
| |
| − | {{tp|p=32329520|t=2020. Current pharmacological treatments for COVID-19: What s next?|pdf=|usr=}}
| |
| − | {{tp|p=32371479|t=2020. Cytokine Storm Drugs Move from CAR T to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303509|t=2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32276929|t=2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?|pdf=|usr=}}
| |
| − | {{ttp|p=32324951|t=2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics |pdf=|usr=}}
| |
| − | {{tp|p=32245590|t=2020. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | ---- | | ---- |
| Zeile 313: |
Zeile 100: |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32189463|t=ä. The possibility of COVID?19 transmission from eye to nose |pdf=|usr=}}
| |
| − | {{tp|p=32189460|t=ä. There may be virus in conjunctival secretion of patients with COVID?19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| Zeile 323: |
Zeile 106: |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32352852|t=2020. Hydrocolloid dressing strip over bridge of nose to relieve pain and pressure from Filtered Face Piece (FFP) masks during the coronavirus (COVID-19) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32366499|t=2020. Covid-19: skin damage with prolonged wear of FFP3 masks |pdf=|usr=}}
| |
| − | {{ttp|p=32371574|t=2020. Facial protection for healthcare workers during pandemics: a scoping review |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32311772|t=2020. Intubation boxes for managing the airway in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32311771|t=2020. Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review |pdf=|usr=}}
| |
| − | {{tp|p=32324055|t=2020. A safe method to evacuate pneumoperitoneum during laparoscopic surgery in suspected COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32380058|t=ä. Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership |pdf=|usr=}}
| |
| − | {{ttp|p=32379080|t=2020. Protecting Surgical Teams During the COVID-19 Outbreak: A Narrative Review and Clinical Considerations |pdf=|usr=}}
| |
| − | {{tp|p=32345617|t=2020. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey |pdf=|usr=}}
| |
| − | {{tp|p=32345619|t=2020. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32219857|t=ä. Advice regarding COVID?19 and use of immunomodulators, in patients with severe dermatological diseases |pdf=|usr=}}
| |
| − | {{tp|p=32376399|t=ä. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion |pdf=|usr=}}
| |
| − | {{tp|p=32376346|t=ä. An In-hospital Pathway for Acute Coronary Syndrome Patients During the COVID-19 Outbreak: Initial Experience under Real-world Suboptimal Conditions |pdf=|usr=}}
| |
| − | {{tp|p=32369287|t=2020. COVID-19: GENERAL GUIDELINES FOR CARDIOVASCULAR SURGEONS (standard guidelines - subject to change) |pdf=|usr=}}
| |
| − | {{tp|p=32223063|t=ä. Italian Society of Interventional Cardiology (GISE) position paper for Cath lab?specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32361152|t=ä. The Use of Bronchoscopy During the COVID-19 Pandemic: CHEST/AABIP Guideline and Expert Panel Report |pdf=|usr=}}
| |
| − | {{tp|p=32253182|t=2020. Social distancing in covid-19: what are the mental health implications?|pdf=|usr=}}
| |
| − | {{tp|p=32345601|t=2020. Covid-19 makes the future of UK clinical research uncertain |pdf=|usr=}}
| |
| − | {{tp|p=32340996|t=2020. Managing patients with rheumatic conditions during the covid-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32330288|t=2020. Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32259402|t=2020. Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32379342|t=2020. Clearing the air: an accessible system for suction and safe evacuation of pneumoperitoneum during laparoscopy in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32363596|t=2020. Safe management of surgical smoke in the age of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32259400|t=2020. Going remote: Maintaining normalcy in our pathology laboratories during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32259387|t=2020. International perspectives: Impact of the COVID-19 pandemic on cytology |pdf=|usr=}}
| |
| − | {{tp|p=32238358|t=2020. Clinical Research Slows as COVID-19 Surges |pdf=|usr=}}
| |
| − | {{tp|p=32209598|t=2020. COVID-19 Challenges Basic Researchers |pdf=|usr=}}
| |
| − | {{tp|p=32332087|t=2020. COVID-19 Hits Cancer Research Funding |pdf=|usr=}}
| |
| − | {{tp|p=32311816|t=2020. Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) |pdf=|usr=}}
| |
| − | {{tp|p=32348003|t=2020. The experience of treating patients with acute myocardial infarction under the COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32348003|t=2020. The experience of treating patients with acute myocardial infarction under the COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32252979|t=2020. Manejo quirurgico de pacientes con infeccion por COVID-19 Recomendaciones de la Asociacion Espanola de Cirujanos |pdf=|usr=}}
| |
| − | {{tp|p=32367794|t=ä. Recommendations for emergency departments receiving patients with vital signs absent from paramedics during COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327003|t=ä. Just the Facts: Protected code blue ? Cardiopulmonary resuscitation in the emergency department during the coronavirus disease 2019 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32360779|t=ä. Low rate of severe acute respiratory syndrome coronavirus 2 spread among health-care personnel using ordinary personal protection equipment in a medium-incidence setting |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32205120|t=2020. Traumatization in medical staff helping with COVID-19 control |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| Zeile 398: |
Zeile 140: |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32298494|t=2020. The role of children in the transmission of mild SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32369541|t=ä. Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review |pdf=|usr=}}
| |
| − | {{tp|p=32267964|t=2020. Infection control in non-clinical areas during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32271600|t=2020. Efficacy of Mass Quarantine as Leverage of Health System Governance During COVID-19 Outbreak: A Mini Policy Review |pdf=|usr=}}
| |
| − | {{tp|p=32371381|t=2020. Covid-19: South Korea relaxes social distancing after the number of new cases drops below 10 a day |pdf=|usr=}}
| |
| − | {{tp|p=32376669|t=2020. Reducing risks from coronavirus transmission in the home-the role of viral load |pdf=|usr=}}
| |
| − | {{tp|p=32366374|t=2020. Covid-19: Deprived areas have the highest death rates in England and Wales |pdf=|usr=}}
| |
| − | {{tp|p=32217520|t=2020. The world s largest refugee camp prepares for covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205334|t=2020. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village |pdf=|usr=}}
| |
| − | {{tp|p=32205309|t=2020. Covid-19: Highest risk patients are asked to stay at home for 12 weeks |pdf=|usr=}}
| |
| − | {{tp|p=32209548|t=2020. Covid-19: UK lockdown is "crucial" to saving lives, say doctors and scientists |pdf=|usr=}}
| |
| − | {{tp|p=32184206|t=2020. Covid-19: Doctors warn of humanitarian catastrophe at Europe s largest refugee camp |pdf=|usr=}}
| |
| − | {{tp|p=32265194|t=2020. Covid-19: Why Germany s case fatality rate seems so low |pdf=|usr=}}
| |
| − | {{tp|p=32368995|t=ä. Mental health and COVID-19: is the virus racist?|pdf=|usr=}}
| |
| − | {{tp|p=32345590|t=2020. Covid-19: undocumented migrants are probably at greatest risk |pdf=|usr=}}
| |
| − | {{tp|p=32312785|t=2020. Is ethnicity linked to incidence or outcomes of covid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32241884|t=2020. Covid-19: four fifths of cases are asymptomatic, China figures indicate |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| Zeile 428: |
Zeile 152: |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32358933|t=2020. Lessons from the USA Delayed Response to the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32144176|t=2020. Trump claims public health warnings on covid-19 are a conspiracy against him |pdf=|usr=}}
| |
| − | {{tp|p=32224494|t=2020. Covid-19: Doctors are told not to perform CPR on patients in cardiac arrest |pdf=|usr=}}
| |
| − | {{tp|p=32205354|t=2020. Clinical trials suspended in UK to prioritise covid-19 studies and free up staff |pdf=|usr=}}
| |
| − | {{tp|p=32107254|t=2020. Covid-19: Trump says risk to Americans is "very low" |pdf=|usr=}}
| |
| − | {{tp|p=32321703|t=2020. The Brazilian slums hiring their own doctors to fight covid-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 450: |
Zeile 167: |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32271601|t=2020. Epidemiology and Clinical Characteristics of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32144096|t=2020. Covid-19: UK records first death, as world s cases exceed 100 000 |pdf=|usr=}}
| |
| − | {{tp|p=32165426|t=2020. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction |pdf=|usr=}}
| |
| − | {{tp|p=32071063|t=2020. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate |pdf=|usr=}}
| |
| − | {{tp|p=32273278|t=2020. Covid-19: should the public wear face masks?|pdf=|usr=}}
| |
| − | {{tp|p=32273267|t=2020. Face masks for the public during the covid-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32265341|t=2020. Covid-19: What is the evidence for cloth masks?|pdf=|usr=}}
| |
| − | {{tp|p=32354787|t=2020. A third of covid-19 patients admitted to UK hospitals die |pdf=|usr=}}
| |
| − | {{tp|p=32327412|t=2020. Covid-19: Two thirds of healthcare workers who have died were from ethnic minorities |pdf=|usr=}}
| |
| − | {{tp|p=32317248|t=2020. Covid-19: doctors are warned not to go public about PPE shortages |pdf=|usr=}}
| |
| − | {{tp|p=32299810|t=2020. Covid-19: Coronavirus was first described in The BMJ in 1965 |pdf=|usr=}}
| |
| − | {{tp|p=32235915|t=2020. COVID-19: a new challenge for human beings |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32220929|t=2020. Guidance needed for singlehanded GPs to deal with covid-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32205317|t=2020. Covid-19: give NHS staff rest spaces and free parking not thank yous, says doctor |pdf=|usr=}}
| |
| − | {{tp|p=32349824|t=ä. The COVID-19 Pandemic: A Month of Bioethics in Finland |pdf=|usr=}}
| |
| − | {{tp|p=32327407|t=2020. Covid-19: BMA demands full death in service benefits for UK doctors |pdf=|usr=}}
| |
| − | {{tp|p=32317305|t=2020. Covid-19: increasing demand for dialysis sparks fears of supply shortage |pdf=|usr=}}
| |
| − | {{tp|p=32354814|t=2020. Viewpoint: COVID-19 This virus is not the real enemy, but our approach to it could be |pdf=|usr=}}
| |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
